Epmedin C, a natural product isolated and purified from the herbs of Epimedium brevicornum Maxim, has estrogen-like effects for ovariectomized mice, and has potential activity against osteoporosis by stimulating osteoblasts.
Epmedin C/淫羊霍定 C 细胞实验
Cell Line
Concentration
Treated Time
Description
References
MC3T3-E1 cells
10, 20 μM
21 days
Evaluate the effect of Epimedin C on mineralization nodule formation, results showed Epimedin C significantly alleviated DEX-induced inhibition of mineralization
Front Pharmacol. 2022 Jul 4;13:894832
MC3T3-E1 cells
10, 20 μM
5 days
Evaluate the effect of Epimedin C on alkaline phosphatase activity, results showed Epimedin C significantly alleviated DEX-induced inhibition of ALP activity
Front Pharmacol. 2022 Jul 4;13:894832
MC3T3-E1 cells
1-60 μM
72 hours
Evaluate the effect of Epimedin C on MC3T3-E1 cell viability, results showed no evident toxicity
Front Pharmacol. 2022 Jul 4;13:894832
Mouse osteoblasts
10 μM
48 hours
Epimedin C enhances migration and proliferation of osteoblasts after DXMS treatment
Aging (Albany NY). 2023 Mar 14;15(6):2033-2045
mouse primary chondrocytes
10, 20 μM
24 hours
To evaluate the protective effect of Epimedin C on IL-1β-induced chondrocyte damage, results showed that Epimedin C significantly improved cell viability, reduced apoptosis, and promoted cell proliferation
Heliyon. 2024 Nov 15;10(23):e40458
human osteoarthritic chondrocytes
25 μM
72 hours
To evaluate the anti-inflammatory and chondroprotective effects of Epimedin C, results showed that Epimedin C significantly increased the expression of collagenous and non-collagenous matrix proteins, demonstrating significant anabolic effects.
Biomolecules. 2020 Jun 19;10(6):932
Epmedin C/淫羊霍定 C 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Mice
Cisplatin-induced intestinal injury model
Gavage
100, 200 mg/kg
10 consecutive days
EFE alleviates cisplatin-induced intestinal injury by modulating oxidative stress, inflammation, and apoptosis
Front Pharmacol. 2022 Oct 12;13:1040504
Kunming (KM) mice
Type 2 diabetes mellitus (T2DM) mouse model
Oral gavage
30 mg/kg
Once daily for 28 days
To evaluate the hypoglycemic effect and mechanism of Epmedin C in T2DM mice. Results showed that Epmedin C significantly reduced fasting blood glucose, HOMA-IR, and oral glucose tolerance, while increasing hepatic glycogen and insulin contents, improving oxidative stress and blood lipid levels.
Nutrients. 2023 Dec 21;16(1):25
C57BL/6 mice
Exercise endurance model
Oral
10ug/kg
Once daily for 10 days
Epimedin C enhanced exercise endurance in mice, prolonging running time
PLoS One. 2025 May 28;20(5):e0325031
C57BL/6J mice
DMM-induced osteoarthritis model
20, 40 mg/kg
8 weeks
To evaluate the therapeutic effect of Epimedin C on DMM-induced osteoarthritis, results showed that Epimedin C significantly preserved cartilage structure, activated Nrf2, and inhibited NLRP3 expression
Heliyon. 2024 Nov 15;10(23):e40458
C57BL/6N mice
Osteoporosis model
Oral
1 × 10−3 μmol/mouse/day
Once daily for 4 weeks
Epimedin C protects against DXMS-induced osteoporosis via the NRF1/RhoA pathway
Aging (Albany NY). 2023 Mar 14;15(6):2033-2045
Zebra fish larvae
DEX-mediated bone impairment model
Dissolved in culture water
10, 20 μM
Evaluate the effect of Epimedin C on bone mineralization in zebra fish larvae, results showed Epimedin C significantly alleviated DEX-induced inhibition of bone mineralization
Front Pharmacol. 2022 Jul 4;13:894832
Balb/c mice
Epmedin C-induced liver injury model
Intragastric administration
10 or 40 mg/kg
Once daily for 4 weeks
Successfully established the Epmedin C-induced liver injury mouse model, characterized by elevated serum aminotransferase levels, increased inflammatory cell infiltration, and vacuolar degeneration in the liver
搜索
